The effect of liraglutide on endothelial function in patients with type 2 diabetes

Debashis Nandy, Christopher Johnson, Rita Basu, Michael Joyner, Jason Brett, Claus Bo Svendsen, Ananda Basu

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

This single-centre, 12-week, double-blind, placebo-controlled trial assessed how the human glucagon-like-peptide 1 analogue liraglutide impacted endothelial function in adult patients (n = 49) with type 2 diabetes and no overt cardiovascular disease. Patients were randomized to liraglutide, placebo or glimepiride. At baseline and Week 12, venous occlusion plethysmography was used to measure forearm blood flow (FBF) in response to acetylcholine (ACh) and sodium nitroprusside (SNP) before and after l-NG-monomethyl arginine (L-NMMA) infusion. At Week 12, ACh-mediated FBF increased with liraglutide and decreased with placebo; however, the between-treatment difference was not significant (p = 0.055). Inhibition of ACh-mediated FBF after L-NMMA infusion increased with liraglutide and decreased with placebo; this between-treatment difference was also not significant (p = 0.149). No change in FBF was observed with SNP. Liraglutide did not significantly impact endothelium-dependent vasodilation after 12 weeks; however, additional investigations looking at the effect of liraglutide on endothelial function in alternative vasculature and during the postprandial period are warranted.

Original languageEnglish (US)
Pages (from-to)419-430
Number of pages12
JournalDiabetes and Vascular Disease Research
Volume11
Issue number6
DOIs
StatePublished - Nov 27 2014

Keywords

  • Glucagon-like peptide-1
  • endothelial function
  • liraglutide

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The effect of liraglutide on endothelial function in patients with type 2 diabetes'. Together they form a unique fingerprint.

  • Cite this